CN105982922A - Composition for treating diabetes and application thereof - Google Patents
Composition for treating diabetes and application thereof Download PDFInfo
- Publication number
- CN105982922A CN105982922A CN201510087591.5A CN201510087591A CN105982922A CN 105982922 A CN105982922 A CN 105982922A CN 201510087591 A CN201510087591 A CN 201510087591A CN 105982922 A CN105982922 A CN 105982922A
- Authority
- CN
- China
- Prior art keywords
- agent
- diabetes
- compositions
- parts
- terms
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The invention discloses a composition for treating diabetes and the application thereof. The composition is prepared from, by weight, 0.05-1 part (based on the content of the microelement Cr) of chromium supplementation agent, 0.005-0.1 part (based on the content of the microelement V) of vanadium supplementation agent, 1-100 parts (based on the content of the microelement Zn) of zinc supplementation agent, and 1-100 parts of vitamin B3. Through combination of the microelements Cr, V and Zn and vitamin B3, the novel composition for treating diabetes is formed. The composition can well treat diabetes and is safe and reliable in clinical tests, cost is low, raw materials are easy to obtain, and the composition is easy to apply and popularize.
Description
Technical field
The present invention relates to belong to pharmaceutical field, be specifically related to a kind of compositions treating diabetes and application thereof.
Background technology
Diabetes are one group of metabolic diseases being characterized with hyperglycemia.Hyperglycemia is then due to insulin secretion
Defect or its biological agent are impaired, or both have concurrently and cause.During diabetes, long-standing hyperglycemia, causes
Various tissues, particularly eye, kidney, heart, blood vessel, neural chronic lesion, dysfunction.1 type or 2
All there is obvious genetic heterogeneity in patients with type Ⅰ DM.There is family's morbidity tendency, 1/4～1/2 patient in diabetes
There is Diabetes family history.The most at least the genetic syndrome of more than 60 kinds can be with diabetes.1 type sugar
Urine disease has multiple DNA site to participate in morbidity, wherein with DQ loci polymorphism relation in HLA antigen gene the most
Closely.Multiple clear and definite gene mutation is had been found that, such as insulin gene, Insulin receptor INSR at type 2 diabetes mellitus
Gene, glucokinase gene, mitochondrial gene etc..Too much, physical exertion reduces the obesity caused in feed
It is the topmost environmental factors of type 2 diabetes mellitus, makes that there is the individual of type 2 diabetes mellitus genetic predisposition and easily send out
Sick.There is immune system abnormality in type 1 diabetes patient, in some virus such as Coxsackie virus, and rubella virus,
Parotid gland virus etc. cause autoimmune response after infecting, destroy insulin β cell.
The method that there is no radical cure diabetes at present, but diabetes can be controlled well by multiple treatment means.Main
Including 5 aspects: the education of diabetics, self-monitoring of blood glucose, Diet Therapy, exercise therapy and
Drug therapy.Drug therapy remains the Main Means of current various treating diabetes, but simultaneous medicine
The toxic and side effects of thing, such as to kidney and the infringement of liver function.In recent years pathogenesis of diabetes mellitus is recognized
Go deep into, provide thinking for developing the medicine of the treatment diabetes acting on novel targets.
But, the medicine of existing treatment diabetes is generally directed to a certain mechanisms play effect, there is treatment
The shortcoming that effect is bad.
Summary of the invention
It is an object of the invention to provide a kind of combination that can effectively treat diabetes for above-mentioned technical problem
Thing.
It is a further object to provide the compositions of above-mentioned effective treatment diabetes at preparation treatment glycosuria
The sick application in medicine, health product or food.
It is an object of the invention to be realized by following technical proposal:
A kind of compositions treating diabetes, said composition contains each component of following weight portion:
Chromium supplementing agent, in terms of trace element Cr: 0.05～1 part,
Vanadium replenishing agent, in terms of trace element V: 0.005～0.1 part,
Zinc supplement agent, in terms of trace elements zn: 1～100 part,
Vitamin B3 1～100 parts.
Further, the compositions of described treatment diabetes preferably comprises each component of following weight portion:
Chromium supplementing agent, in terms of trace element Cr: 0.1～0.5 part,
Vanadium replenishing agent, in terms of trace element V: 0.03～0.08 part,
Zinc supplement agent, in terms of trace elements zn: 10～50 parts,
Vitamin B3 10～50 parts.
Optimum, the compositions of described treatment diabetes contains each component of following weight portion:
Chromium supplementing agent, in terms of trace element Cr: 0.2 part,
Vanadium replenishing agent, in terms of trace element V: 0.05 part,
Zinc supplement agent, in terms of trace elements zn: 20 parts,
Vitamin B3 30 parts.
Preferably, one or both during described chromium supplementing agent is Rich chromium yeast, chromium glycine, chromium picolinate
Above mixture, it is for improving the content of the trace element chromium in human body.
Preferably, a kind of during described vanadium replenishing agent is pyridine carboxylic acid vanadyl or vanadium oxysulfate or both mixture
It is for improving the content of the trace element vanadium in human body.
Preferably, described zinc supplement agent is in yeast rich in zinc, zinc gluconate, zinc lactate or zinc citrate
Kind or two or more mixture, it is for improving the content of the trace element zinc in human body.
The dosage form of the compositions of described treatment diabetes is pharmacy or any dosage form of health product permission, is preferably
Tablet, capsule, granule, powder, pill, oral liquid, injection or membrane.
Present invention also offers the compositions of described treatment diabetes in preparation the treatment medicine of diabetes, health care
Application in product or food.
Chromium is the trace element of needed by human, and it plays a crucial role in terms of maintaining health.The physiology of chromium
Function is to coordinate and work together with other material controlling metabolism, as hormone, insulin, various enzyme,
The genetic stew (DNA and RNA) etc. of cell.Chromium content in human body is about 7 milligrams, is distributed mainly on
Among skeleton, skin, adrenal gland, brain and muscle.Chromium as the micronutrient element of a kind of necessity in institute
Having in insulin regulation activity and play an important role, it can help insulin to promote the glucose intracellular effect of entrance
Rate, is important blood sugar regulator.It contributes to growth promoter, and also has the cholesterol concentration in blood
Control action, may result in heart disease during shortage.Chromium or the constituent of glucose tolerance factor,
It can promote that insulin plays a role the most fully.Physiologically for the growth promoter of body, pancreas
Island element and growth hormone are of equal importance, indispensable.Insulin effect in human body is very big, is body
Interior important synthetic hormone can promote the picked-up of glucose, stores and utilize, and can promote again the synthesis of fatty acid,
Synthesis and the storage of protein can also be promoted.
Vanadium is the mineral that normal growth may be required, extremely low at people's in-vivo content, internal insufficient total amount 1mg.
Being distributed mainly on internal organs, especially the position such as liver, kidney, thyroid, in osseous tissue, content is the highest.Vanadium is also
Carbohydrate metabolism can be promoted, stimulate vanadate dependency NADPH oxidation reaction, strengthen lipoprotein lipase activity,
Accelerate adenyl cyclase activation to act on amino acid converting and promotion red blood cell growth etc..Therefore when vanadium lacks
May occur in which that tooth, bone and cartilage development are obstructed.In liver, content of phospholipid is few, nutritional edema and thyroid
Developmental and Metabolic Disorder etc..In many biochemical processes, vanadic acid root can be competed with phosphate radical, or replaces phosphate radical.Vanadium
Hydrochlorate is to be reduced by vitamin C, glutathion or NADH.Its effect in terms of health, threpsology
Boundary, medical circle is the most still not very clear, is still in during excavating further, but it was determined that vanadium
Play an important role.It is generally believed that it potentially contributes to prevent Cholesterol Accumulation, reduces too high blood glucose, anti-
Only dental caries, help manufacture erythrocyte etc..
Zinc is one of trace element of needed by human, in growth in humans's growth, reproduction heredity, immunity, endocrine
Play an important role etc. in important physiological process.Zinc is present in numerous enzyme systems, as carbonic anhydrase,
During respiratory enzyme, lactate dehydrogenase, superoxide dismutase, alkali phosphatase, DNA and RNA are poly-in enzyme etc.,
It is nucleic acid, protein, the synthesis of carbohydrate and the required material of vitamin A utilization.There is promotion raw
Long growth, improves the effect of the sense of taste.Easily occur during zinc deficiency that sense of taste olfactory sensation is poor, anorexia, poor growth and intelligence
Grow and wait performance less than normal, also can cause lower for the resistance, and cause other various diseases.
Vitamin B3 is also nicotinic acid, is one of 13 kinds of vitamin of needed by human, is that a kind of water soluble vitamin is raw
Element, belongs to vitamin B complex.Nicotinic acid is converted into nicotiamide in human body, and nicotiamide is cozymase and codehydrogenase Ⅱ
Ingredient, participate in HypercholesterolemicRats, the oxidizing process of Tissue respiration and the process of saccharide anaerobic decomposition.
People lacks nicotinic acid will cause pellagra.Its classical symptom is symmetry dermatitis, diarrhea and dementia (three D symptoms).
Their early stage loses weight, unable, oral cavity and tongue burn feeling, dyspepsia, stomachache, diarrhea, mistake
Sleep, headache, forgetful, irritated etc..The skin rubefaction that exposes therewith, itch, similar sunburn.Long skin
Becoming kermesinus or brown, have pigmentation, desquamation etc., it is peculiar that these show as primary disease institute.Have has
Secondary infection, muscular tremor, also can spiritedness not normal, show manic, suspect, obnubilation etc..
The present invention treats the compositions of diabetes and trace element Cr, V, Zn and vitamin B3 is combined,
Form the compositions with treatment diabetes effect that a class is new.Said composition also has relatively in clinical trial
Good treatment diabetes effect and safe and reliable, low cost, raw material is easy to get, it is easy to popularization and application.
The raw material of preparation said composition is used equally to food, therefore, its few side effects, raw material sources are extensive,
Preparation method is simple, it is simple to industrialized production.
The instructions of taking of the compositions of the treatment diabetes of the present invention is: dose is 135mg～540mg/ day,
Take with meal at twice.
Detailed description of the invention
Below in conjunction with specific embodiment, the present invention is described, it should be noted that these embodiments are only used for
The bright present invention should not be construed as limitation of the present invention.
Any form not taking compositions but take respectively each raw material according to the present invention record consumption be provided commonly for
The situation of the treatment medicine of diabetes, health product or food falls within the content of present invention protection.
Being 1 part with 1mg in following preparation example, the preparation technology of various dosage forms and adjuvant select to be existing skill
Art.
The molecular weight 52 of Cr, chromium glycine (Cr (C2H4NO2)3) molecular weight 274.17, chromium picolinate
(Cr(C6H4NO2)3) molecular weight 418.30；
The molecular weight 50.94 of V, pyridine carboxylic acid vanadyl ((C6H4O2N)2OV) molecular weight 311.15, sulphuric acid
Vanadyl (VOSO4) molecular weight 163.00.
The molecular weight 65.38 of Zn, zinc gluconate (C12H22O14Zn) molecular weight 455.69, zinc lactate
(C6H10ZnO6·3H2O) molecular weight 297.38, zinc citrate (Zn3(C6H6O7)2·2H2O) molecule
Amount 610.37；
In Rich chromium yeast the content of chromium be 0.2wt% (wt%, weight/mass percentage composition, lower with).
In yeast rich in zinc, the content of zinc is 2wt%.
These materials of food stage all can be bought from market and obtain.
Embodiment 1
By Rich chromium yeast 25 parts, pyridine carboxylic acid vanadyl 0.03 part, zinc citrate 9.34 parts and vitamin B3
The ratio of 1 part takes each component, adds 2.5 parts of magnesium stearate, 5 parts of starch, suitable quantity of water, mix homogeneously, pressure
Sheet, obtains tablet.Embodiment 2
By chromium glycine 5.3 parts, vanadium oxysulfate 0.32 part, zinc lactate 455 parts and vitamin B3 100
Part ratio take each component, add 30 parts of microcrystalline Cellulose, 40 parts of dextrin, suitable quantity of water, mix homogeneously,
Soft material processed, extrusion spheronization method is pelletized, is obtained granule.
Embodiment 3
By chromium picolinate 1.6 parts, pyridine carboxylic acid vanadyl 0.3 part, yeast rich in zinc 1000 parts and vitamin
The ratio of B330 part takes each component, is dissolved in water, and adds stevioside seasoning, adds water to 500ml, filters,
Fill (5ml/ props up), sealing, 105 DEG C of flowing steam sterilizings, obtain oral liquid.
Embodiment 4
By chromium glycine 1.1 parts, vanadium oxysulfate 0.2 part, yeast rich in zinc 1000 parts and vitamin B3 30
The ratio of part takes each component, adds 100 parts of flour, 50 portions of sucrose, suitable quantity of water, mix homogeneously, dries,
Make cookies.
Embodiment 5
By Rich chromium yeast 100 parts, pyridine carboxylic acid vanadyl 0.3 part, zinc gluconate 140 parts and vitamin B3
The ratio of 30 parts takes each component, adds 40 parts of microcrystalline Cellulose, 35 parts of magnesium stearate, 30 parts of poly-dimensions of crosslinking
Ketone, suitable quantity of water, mix homogeneously, mist projection granulating, fill capsule, obtain capsule.
Embodiment 6
By Rich chromium yeast 50 parts, pyridine carboxylic acid vanadyl 0.03 part, vanadium oxysulfate 0.08 part, yeast rich in zinc
500 parts take each component with the ratio of vitamin B3 10 parts, add 80 parts of microcrystalline Cellulose, 70 parts of stearic acid
Magnesium, 60 parts of polyvinylpolypyrrolidone, suitable quantity of water, mix homogeneously, mist projection granulating, fill capsule, obtain capsule.
Embodiment 7
By Rich chromium yeast 100 parts, chromium glycine 1.6 parts, pyridine carboxylic acid vanadyl 0.48 part, vanadium oxysulfate
0.08 part, the ratio of zinc gluconate 140 parts, zinc lactate 136 parts and vitamin B3 50 parts takes each component,
Add 60 parts of microcrystalline Cellulose, 50 parts of magnesium stearate, 45 parts of polyvinylpolypyrrolidone, suitable quantity of water, mix homogeneously,
Mist projection granulating, fill capsule, obtain capsule.
Part in various embodiments above is weight portion.
Experimental example
The present invention treats the compositions of diabetes curative effect in diabetic
Experimental technique: object of study is for accepting to control in Beijing hospital in December, 2014 from January, 2013
The type 2 diabetes mellitus patient treated, totally 330 example.In age 30-60 year, meet the diagnostic criteria of diabetes, nothing
Severe physical disease, ethanol or drug dependence, without other severe psychiatric diseases.All patients all sign in the know
Letter of consent.
Application area group randomized grouping method, the patient that the course of disease is close is randomized into seminar and matched group.Altogether
22 groups, often organize 15 examples, matched group (normally taking antidiabetic drug metformin, dose is each 0.5g,
Every day 2 times, take with meal) and seminar's embodiment 1-7 low (dose is 135mg/ day), in (clothes
Consumption is 270mg/ day), high (540mg/ day) group, the low middle high group of seminar's embodiment 1-7 is taken respectively
Compositions in embodiment 1-7.Day dose is also divided into secondary every day by seminar, takes with meal.22
The equal not statistically significants of difference (P > 0.05) such as group patient age, sex and blood sugar level.All patients give
Regular diabetic diet, carries out health education and appropriate exercise is taken exercise.Before the treatment and treatment two weeks after,
Early morning measures the blood sugar level of patient on an empty stomach.
Experimental result: the blood sugar level of seminar and matched group is shown in Table 1.After treatment two weeks, implement
The seminar of the low middle high dose of example 1-7 is the most statistically significant with matched group difference compared with before treatment,
P < 0.01 and P < 0.001.The especially best results of the middle dosage group of embodiment 5, even better than diformazan is double
Guanidine drug control group.Illustrate that the compositions of the treatment diabetes of the present invention has the work significantly treating diabetes
With.
Blood sugar level before and after table 1. seminar and treatment of control group (mmol/L))
Before * P < 0.01, * * * P < 0.001vs treatment
Last it is noted that above example is only in order to illustrate technical scheme, rather than it is limited
System；Although the present invention being described in detail with reference to previous embodiment, those of ordinary skill in the art
It is understood that the technical scheme described in foregoing embodiments still can be modified by it, or to it
Middle part technical characteristic carries out equivalent；And these amendments or replacement, do not make appropriate technical solution
Essence departs from the spirit and scope of various embodiments of the present invention technical scheme.
Claims (9)
1. the compositions treating diabetes, it is characterised in that said composition contains each of following weight portion
Component:
Chromium supplementing agent, in terms of trace element Cr: 0.05～1 part,
Vanadium replenishing agent, in terms of trace element V: 0.005～0.1 part,
Zinc supplement agent, in terms of trace elements zn: 1～100 part,
Vitamin B3 1～100 parts.
The compositions for the treatment of diabetes the most according to claim 1, it is characterised in that said composition contains
There is each component of following weight portion:
Chromium supplementing agent, in terms of trace element Cr: 0.1～0.5 part,
Vanadium replenishing agent, in terms of trace element V: 0.03～0.08 part,
Zinc supplement agent, in terms of trace elements zn: 10～50 parts,
Vitamin B3 10～50 parts.
The compositions for the treatment of diabetes the most according to claim 2, it is characterised in that said composition contains
The material of following weight portion:
Chromium supplementing agent, in terms of trace element Cr: 0.2 part,
Vanadium replenishing agent, in terms of trace element V: 0.05 part,
Zinc supplement agent, in terms of trace elements zn: 20 parts,
Vitamin B3 30 parts.
4. according to the compositions of the treatment diabetes described in any one of claim 1-3, it is characterised in that
Described chromium supplementing agent is one or more the mixture in Rich chromium yeast, chromium glycine, chromium picolinate.
5. according to the compositions of the treatment diabetes described in any one of claim 1-3, it is characterised in that
Described vanadium replenishing agent is a kind of in pyridine carboxylic acid vanadyl or vanadium oxysulfate or both mixture.
6. according to the compositions of the treatment diabetes described in any one of claim 1-3, it is characterised in that
Described zinc supplement agent is one or more in yeast rich in zinc, zinc gluconate, zinc lactate or zinc citrate
Mixture.
7. according to the compositions of the treatment diabetes described in any one of claim 1-3, it is characterised in that
Its dosage form is pharmacy or any dosage form of health product permission.
The compositions for the treatment of diabetes the most according to claim 7, it is characterised in that its dosage form is sheet
Agent, capsule, granule, powder, pill, oral liquid, injection or membrane.
9. the compositions of the treatment diabetes described in any one of claim 1-8 is in preparation treatment diabetes
Application in medicine, health product or food.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510087591.5A CN105982922A (en) | 2015-02-25 | 2015-02-25 | Composition for treating diabetes and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510087591.5A CN105982922A (en) | 2015-02-25 | 2015-02-25 | Composition for treating diabetes and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105982922A true CN105982922A (en) | 2016-10-05 |
Family
ID=57038258
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510087591.5A Pending CN105982922A (en) | 2015-02-25 | 2015-02-25 | Composition for treating diabetes and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105982922A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1814167A (en) * | 2005-12-12 | 2006-08-09 | 张恩及 | Health-care for diabetes |
| CN102783636A (en) * | 2012-06-04 | 2012-11-21 | 于长富 | Food nutrition supplement for prophylaxis and treatment of diabetes and application thereof |
| CN103431392A (en) * | 2013-08-29 | 2013-12-11 | 青岛海百合生物技术有限公司 | Composite marine food for special dietary uses for diabetics |
-
2015
- 2015-02-25 CN CN201510087591.5A patent/CN105982922A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1814167A (en) * | 2005-12-12 | 2006-08-09 | 张恩及 | Health-care for diabetes |
| CN100374140C (en) * | 2005-12-12 | 2008-03-12 | 张恩及 | Health-care for diabetes |
| CN102783636A (en) * | 2012-06-04 | 2012-11-21 | 于长富 | Food nutrition supplement for prophylaxis and treatment of diabetes and application thereof |
| CN103431392A (en) * | 2013-08-29 | 2013-12-11 | 青岛海百合生物技术有限公司 | Composite marine food for special dietary uses for diabetics |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104257696B (en) | A kind of steady sugar yeast bacterium powder of hypoglycemic and its preparation method and application | |
| WO2023005911A1 (en) | Nucleotide composition for adjuvant treatment of diabetes, preparation method therefor, and use thereof | |
| JP2019210269A (en) | Composition for treating diabetic disease | |
| CN107712909A (en) | A kind of iron zinc Muti-vitamine Oral Solution | |
| CN105982921A (en) | Composition for treating gout and application thereof | |
| CN110384240A (en) | Hypoglycemic vitamin and probiotics fermention object powder alimentation composition and its application | |
| CN101129406A (en) | Formula of compound colla carapaeis corii asini series products and method for producing the same | |
| CN105982922A (en) | Composition for treating diabetes and application thereof | |
| CN102578451A (en) | Health-care food composite capable of decreasing blood sugar | |
| CN105248944A (en) | Production method of potassium-rich and carotene-rich eggs | |
| US7998500B2 (en) | Nutritional supplement for women | |
| CN107595829B (en) | A kind of composition for preventing and treating renal osteodystrophy | |
| CN108079000A (en) | A kind of pharmaceutical composition for treating diabetes and preparation method thereof | |
| CN101204400A (en) | Prescripton and preparing method of colla corii asini line products | |
| CN114028434A (en) | A composition for treating diabetes | |
| CN104970372A (en) | Vitamin and mineral tablets for pregnant woman and wet nurse | |
| CN111214600A (en) | Blood sugar reducing formula containing Chinese yam | |
| CN113170898A (en) | Health-care composition assisting in reducing blood sugar and blood fat and health-care product thereof | |
| CN101375907B (en) | Pharmaceutical combination for preventing birth-defect and improving memory | |
| CN104095178A (en) | Composition used for assistant reduction of blood sugar | |
| CN108464502A (en) | A kind of food and its preparation method and application suitable for diabetic | |
| CN101342211A (en) | Pharmaceutical composition for preventing birth defection and improving memory | |
| CN101045135A (en) | Medicine use for improving memory and treating senile dementia due to encephalatrophy | |
| CN108524536A (en) | A kind of pharmaceutical composition and preparation method thereof for treating diabetes | |
| EP3600256A1 (en) | Nutraceutical compositions for dysmetabolic diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20200812 Address after: Room 101, building 2, tonghuang Road, Liucun Town, Daxing District, Beijing 102600 Applicant after: Beijing Jung Psychological Consulting Co., Ltd Address before: 100062 Beijing City, Dongcheng District guangqumenwai Nanxiaojie No. 1 floor 3 No. 1-302 Applicant before: BEIJING SHIJIAN UNITED MEDICAL SCIENCE Research Institute (GENERAL PARTNERSHIPMENT) Applicant before: Tao Ran Applicant before: Li Huan |
|
| TA01 | Transfer of patent application right | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20161005 |
|
| RJ01 | Rejection of invention patent application after publication |